Study results show conjugate therapy produced remissions in one-third of patients with drug-resistant ovarian cancer
by Dana-Farber Cancer InstituteAntitumor activity of mirvetuximab soravtansine. (A) Maximum percentage change in target lesion size from baseline. Best response according to RECIST is indicated b
Updated on: January 30,2024
18

Study results show conjugate therapy produced remissions in one-third of patients with drug-resistant ovarian cancer
by Dana-Farber Cancer InstituteAntitumor activity of mirvetuximab soravtansine. (A) Maximum percentage change in target lesion size from baseline. Best response according to RECIST is indicated b
Updated on:January 30,2024
18
